cilgavimab and tixagevimab drug combination

a mixture of two SARS-CoV-2 neutralizing antibodies

Also Known As:

AZD 7442; AZD-7442; AZD1061 and AZD8895; AZD7442; Evusheld; cilgavimab and tixagevimab antibody combination; cilgavimab and tixagevimab mixture; cilgavimab, tixagevimab drug combination; tixagevimab and cilgavimab antibody combination; tixagevimab and cilgavimab drug combination; tixagevimab and cilgavimab mixture

Networked: 63 relevant articles (13 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Esser, Mark T: 3 articles (01/2022 - 01/2022)
2.	Pilla Reddy, Venkatesh: 2 articles (12/2022 - 01/2022)
3.	Arends, Rosalinda H: 2 articles (01/2022 - 01/2022)
4.	Crowe, James E: 2 articles (01/2022 - 01/2022)
5.	Kelly, Elizabeth J: 2 articles (01/2022 - 01/2022)
6.	Loo, Yueh-Ming: 2 articles (01/2022 - 01/2022)
7.	Pangalos, Menelas N: 2 articles (01/2022 - 01/2022)
8.	Ren, Kuishu: 2 articles (01/2022 - 01/2022)
9.	Rosenthal, Kim: 2 articles (01/2022 - 01/2022)
10.	Streicher, Katie: 2 articles (01/2022 - 01/2022)

Related Diseases

1.	COVID-19 09/01/2023 - "AZD7442 reduced progression of COVID-19 symptoms versus placebo through to day 29 (RRR 12.5%; 95% CI 0.5, 23.0) and improved most symptoms within 1-2 weeks. " 01/01/2023 - "This study suggests that Evusheld is effective in reducing the risk of SARS-CoV-2 infection and COVID-19 hospitalization in immunocompromised patients. " 11/19/2021 - "Covid-19: AstraZeneca says its antibody drug AZD7442 is effective for preventing and reducing severe illness." 01/01/2022 - "A single dose of AZD7442 had efficacy for the prevention of Covid-19, without evident safety concerns. " 12/01/2023 - "Following this study, AZD7442 was tested in larger clinical trials to investigate its potential in preventing and treating COVID-19. "
2.	Infections 01/01/2023 - "The results of one-way sensitivity analysis indicated that the cost-effectiveness of Evusheld was sensitive to changes in the rate of infection, cost and efficacy of Evusheld, proportion of inadequate immune responses, and the probability of moving from a 'recovered' to 'susceptible' status. " 01/01/2023 - "We also observed that Evusheld recipients displayed elevated antibody levels in their serum, which efficiently neutralized the original variant, and exhibited different characteristics of infection than those who did not receive Evusheld. " 01/01/2023 - "AZD7442 among ICIs may protect against Omicron variant infection and severe disease and should be considered for pre-exposure prophylactic AZD7442." 01/01/2023 - "Rates of infection and severe disease were compared between those administered AZD7442 and those who did not respond to the invitation over a 3-month period. " 01/01/2023 - "Evusheld helped prevent COVID-19 infection, severe infection, and death in all three patient groups. "
3.	Hypersensitivity (Allergy) 08/14/2023 - "We estimated the cost-effectiveness of Evusheld in key risk populations: 1) immunocompromised (vaccinated/unvaccinated), 2) severe allergic reaction, and 3) unvaccinated elderly high-risk groups. " 08/14/2023 - "Our study demonstrated that Evusheld treatment for COVID-19 infection in South Korea is highly cost-effective for unvaccinated risk groups ($18,959 per QALY gained for immunocompromised and $23,978 per QALY gained for high-risk elderly groups) and moderately cost-effective among individuals who are vaccinated immunocompromised ($46,494 per QALY gained), or have severe allergic reactions ($45,996 per QALY gained). " 11/01/2022 - "Hypersensitivity reactions with tixagevimab/cilgavimab (Evusheld)." 08/14/2023 - "Tixagevimab and cilgavimab (Evusheld) administration is a recommended strategy for unvaccinated patients with immunocompromised conditions and severe allergic reaction conditions to protect high-risk individuals and control the coronavirus disease 2019 (COVID-19) epidemic. "
4.	Neoplasms (Cancer) 01/01/2023 - "Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies." 01/01/2023 - "The promising results obtained during in vitro testing led to the authorization of the off-label use of Evusheld, which made the patient negative for SARS-CoV-2, thus, allowing him to resume his cancer treatment. " 01/01/2023 - "Next, we discuss efforts made at the patient, health system, and population levels to mitigate the effects of the ongoing outbreak for patients with cancer, including (1) screening, barrier and isolation strategies (2), Masking/PPE (3), vaccination, and (4) systemic therapies (e.g., evusheld) to prevent disease onset in patients. " 11/01/2023 - "We performed a retrospective study of 892 high-risk hematologic malignancy patients who received AZD7442 at Memorial Sloan Kettering Cancer Center in New York City from January 1, 2022 to July 31, 2022. " 01/01/2023 - "In order to resume cancer treatment and make the patient free from SARS-CoV-2, an in vitro screening of Evusheld monoclonal antibodies (tixagevumab-cilgavimab) against the viral strains isolated from the subject was performed. "
5.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 07/01/2023 - "The real-world efficacy of Evusheld in patients with inflammatory bowel disease (IBD) is not known. " 07/01/2023 - "Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study."

Related Drugs and Biologics

1.	cilgavimab
2.	tixagevimab
3.	Monoclonal Antibodies
4.	N-methyl-valyl-amiclenomycin (BA 2)
5.	N-(2-cyanoethylene)urea (BA 1)
6.	nirmatrelvir and ritonavir drug combination
7.	Neutralizing Antibodies
8.	molnupiravir
9.	Vaccines
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics
2.	Off-Label Use
3.	Renal Dialysis (Hemodialysis)
4.	Hematopoietic Stem Cell Transplantation
5.	Intramuscular Injections